Upcoming Consensus on Minimal Residual Disease (MRD) Testing Confirms Black Swan Approach

The IMF's Black Swan Research Initiative® moves a major step forward with the imminent publication of new myeloma response criteria using minimal residual disease (MRD) testing. In his blog this week, IMF Chairman Dr. Brian Durie explains the significance of this consensus by more than 200 top myeloma experts and why it confirms the Black Swan approach, and offers a snapshot of MRD testing for patients wondering if it's ready for “prime time.”

Source: International Myeloma Foundation - July 15, 2016 Category: Hematology Source Type: news